9 documents

Read All
08:00 , Feb 13, 2012 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Mylan deal

Valeant divested generic versions of dermatology drugs BenzaClin clindamycin/benzoyl peroxide gel and Efudex fluorouracil cream to Mylan. The deal includes an ANDA for generic BenzaClin to treat acne and a license to manufacture and market...
Read More
07:00 , Jul 18, 2011 |  BC Week In Review  |  Company News

Valeant Pharmaceuticals, Sanofi deal

Valeant will acquire Sanofi's Dermik dermatology unit for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had total 2010 revenue of about $240 million. Valeant...
Read More
00:18 , Jul 12, 2011 |  BC Extra  |  Company News

Sanofi sells dermatology business to Valeant

Valeant Pharmaceuticals International Inc. (TSX:VRX; NYSE:VRX) acquired the Dermik dermatology unit from Sanofi (Euronext:SAN; NYSE:SNY) for $425 million in cash. Dermik, which markets therapeutic and aesthetic dermatology products mainly in the U.S. and Canada, had...
Read More
08:00 , Jan 18, 2010 |  BC Week In Review  |  Company News

A.P. Pharma, Paul Capital Partners deal

A.P. Pharma received the final $2.5 million milestone payment from Paul Capital's Paul Royalty Fund under a 2005 deal in which Paul Capital purchased royalty rights to A.P. Pharma's acne drug Retin-A Micro and actinic...
Read More
07:00 , Sep 8, 2008 |  BioCentury  |  Regulation

Refinement wanted

Refinement wanted As mandated by the FDA Amendments Act of 2007, FDA last week released its first quarterly report on potential signals of risk for marketed drugs. Under FDAAA, the agency must report new safety...
Read More
07:00 , Jun 11, 2007 |  BC Week In Review  |  Company News

A.P. Pharma, Paul Capital Partners deal

APPA received a $2.5 million milestone payment from Paul Capital's Paul Royalty Fund under a deal in which Paul Capital purchased royalty rights to acne drug Retin-A Micro and actinic keratosis drug Carac (see BioCentury,...
Read More
08:00 , Jan 23, 2006 |  BC Week In Review  |  Company News

A.P. Pharma, J&J, Paul Capital Partners sales and marketing update

A.P. Pharma Inc. (APPA), Redwood City, Calif.   Johnson & Johnson (JNJ), New Brunswick, N.J.   Paul Capital Partners , New York, N.Y.   Business: Dermatology   Paul Capital's Paul Royalty Fund purchased royalty rights...
Read More
08:00 , Feb 28, 2005 |  BC Week In Review  |  Clinical News

Carac 5-fluorouracil dermatology data

Data from a 12-month, placebo-controlled study in 142 patients showed that treatment with 0.5% Carac cream prior to cryosurgery is significantly more effective in reducing AK lesions than placebo plus cryosurgery. After 4 weeks, mean...
Read More
07:00 , Apr 16, 2001 |  BC Week In Review  |  Company News

Advanced Polymer sales and marketing update

APOS partner Dermik Laboratories Inc., a subsidiary of Aventis S.A. (AVE, Strasbourg, France), launched APOS's Carac Microsponge formulation of 5-FU to treat actinic keratoses. APOS will receive royalties. Advanced Polymer Systems Inc. (APOS), Redwood City,...
Read More